BR0214412A - Solução para injeção de um antagonista de lhrh - Google Patents

Solução para injeção de um antagonista de lhrh

Info

Publication number
BR0214412A
BR0214412A BR0214412-3A BR0214412A BR0214412A BR 0214412 A BR0214412 A BR 0214412A BR 0214412 A BR0214412 A BR 0214412A BR 0214412 A BR0214412 A BR 0214412A
Authority
BR
Brazil
Prior art keywords
lhrh antagonist
solution
injection
lhrh
antagonist
Prior art date
Application number
BR0214412-3A
Other languages
English (en)
Other versions
BRPI0214412B1 (pt
BRPI0214412B8 (pt
Inventor
Werner Sarlikiotis
Horst Bauer
Matthias Rischer
Juergen Engel
Frank Guethlein
Dominique Di Stefano
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of BR0214412A publication Critical patent/BR0214412A/pt
Publication of BRPI0214412B1 publication Critical patent/BRPI0214412B1/pt
Publication of BRPI0214412B8 publication Critical patent/BRPI0214412B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"SOLUçãO PARA INJEçãO DE UM ANTAGONISTA DE LHRH". A presente invenção refere-se a uma solução aquosa para injeção que compreende o antagonista de LHRH contém além do antagonista de LHRH, tal como o cetrorelix, um ácido orgânico compatível de forma fisiológica, e de modo opcional um tensoativo e também um enchimento de construção de estrutura. O antagonista de LHRH tem a solubilidade aumentada de forma significativa e pode ser preparado em concentrações mais elevadas e com uma biodisponibilidade aumentada. A tendência de agregação do antagonista de LHRH é reduzida de forma significativa.
BRPI0214412A 2001-11-26 2002-11-15 solução aquosa contendo ácido glicônico, manitol e tween 80 para injeção de antagonista de hormônio liberador de gonadotrofina (lhrh), bem como seu processo de preparação BRPI0214412B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10157628A DE10157628A1 (de) 2001-11-26 2001-11-26 Injektionslösung eines LHRH-Antagonisten
PCT/EP2002/012798 WO2003045419A1 (de) 2001-11-26 2002-11-15 Injektionslösung eines lhrh-antagonisten

Publications (3)

Publication Number Publication Date
BR0214412A true BR0214412A (pt) 2004-09-14
BRPI0214412B1 BRPI0214412B1 (pt) 2016-01-05
BRPI0214412B8 BRPI0214412B8 (pt) 2021-05-25

Family

ID=7706799

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0214412A BRPI0214412B8 (pt) 2001-11-26 2002-11-15 solução aquosa contendo ácido glicônico, manitol e tween 80 para injeção de antagonista de hormônio liberador de gonadotrofina (lhrh), bem como seu processo de preparação

Country Status (33)

Country Link
EP (1) EP1448221B1 (pt)
JP (1) JP4343693B2 (pt)
KR (1) KR100936636B1 (pt)
CN (1) CN100404068C (pt)
AR (1) AR037424A1 (pt)
AT (1) ATE350050T1 (pt)
AU (1) AU2002365504B2 (pt)
BR (1) BRPI0214412B8 (pt)
CO (1) CO5580793A2 (pt)
CY (1) CY1106401T1 (pt)
DE (2) DE10157628A1 (pt)
DK (1) DK1448221T3 (pt)
EA (1) EA010787B1 (pt)
ES (1) ES2276970T3 (pt)
GE (1) GEP20063861B (pt)
HK (1) HK1073078A1 (pt)
HR (1) HRP20040587B1 (pt)
HU (1) HU230992B1 (pt)
IL (2) IL161894A0 (pt)
IS (1) IS2725B (pt)
ME (1) ME00499B (pt)
MX (1) MXPA04005018A (pt)
NO (1) NO333364B1 (pt)
NZ (1) NZ533712A (pt)
PL (1) PL206199B1 (pt)
PT (1) PT1448221E (pt)
RS (1) RS51408B (pt)
RU (1) RU2322969C2 (pt)
SI (1) SI1448221T1 (pt)
TW (1) TWI312283B (pt)
UA (1) UA81612C2 (pt)
WO (1) WO2003045419A1 (pt)
ZA (1) ZA200404051B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
ES2426445T3 (es) 2006-04-07 2013-10-23 Merrion Research Iii Limited Forma de dosificación oral sólida que contiene un potenciador
US8999383B2 (en) * 2008-05-07 2015-04-07 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012094598A2 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CN103690560B (zh) * 2013-12-17 2016-08-17 辽宁海思科制药有限公司 一种转化糖电解质注射液药物组合物及其制备方法
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
RU2614234C2 (ru) * 2015-03-31 2017-03-23 Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) Фармацевтическая композиция на основе 3-(4-Метилимидазол-1-ил)имидазо[1,2-b][1,2,4,5]тетразина в качестве противоопухолевого средства
KR20210157482A (ko) * 2017-01-30 2021-12-28 안테브 리미티드 적어도 하나의 gnrh 길항제를 포함하는 조성물
DK3811927T3 (da) 2019-10-24 2021-12-13 Sun Pharmaceutical Ind Ltd Stabil, parenteral doseringsform af cetrorelixacetat

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US5300492A (en) * 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
KR100772852B1 (ko) * 1999-09-23 2007-11-02 젠타리스 게엠베하 자궁내막증 치료용 약제학적 조성물
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung

Also Published As

Publication number Publication date
WO2003045419A1 (de) 2003-06-05
PL369548A1 (en) 2005-05-02
EA200400742A1 (ru) 2004-12-30
DK1448221T3 (da) 2007-03-19
ATE350050T1 (de) 2007-01-15
BRPI0214412B1 (pt) 2016-01-05
HRP20040587A2 (en) 2004-10-31
CN1592630A (zh) 2005-03-09
AU2002365504B2 (en) 2007-06-28
IS7251A (is) 2004-05-06
UA81612C2 (ru) 2008-01-25
TWI312283B (en) 2009-07-21
IS2725B (is) 2011-03-15
HUP0401986A2 (hu) 2005-01-28
DE50209193D1 (de) 2007-02-15
ES2276970T3 (es) 2007-07-01
SI1448221T1 (sl) 2007-06-30
CN100404068C (zh) 2008-07-23
KR100936636B1 (ko) 2010-01-14
HU230992B1 (hu) 2019-08-28
JP2005510544A (ja) 2005-04-21
ME00499B (me) 2011-10-10
PT1448221E (pt) 2007-03-30
EP1448221A1 (de) 2004-08-25
AU2002365504A1 (en) 2003-06-10
MXPA04005018A (es) 2004-08-11
NO20042449L (no) 2004-06-11
RS44904A (en) 2006-10-27
RU2004119821A (ru) 2005-04-20
HUP0401986A3 (en) 2012-09-28
KR20040058312A (ko) 2004-07-03
PL206199B1 (pl) 2010-07-30
NZ533712A (en) 2006-01-27
CY1106401T1 (el) 2011-10-12
NO333364B1 (no) 2013-05-13
RS51408B (sr) 2011-02-28
AR037424A1 (es) 2004-11-10
HRP20040587B1 (en) 2008-01-31
EP1448221B1 (de) 2007-01-03
JP4343693B2 (ja) 2009-10-14
ZA200404051B (en) 2005-05-25
HK1073078A1 (en) 2005-09-23
BRPI0214412B8 (pt) 2021-05-25
RU2322969C2 (ru) 2008-04-27
TW200300352A (en) 2003-06-01
DE10157628A1 (de) 2003-06-12
GEP20063861B (en) 2006-06-26
IL161894A0 (en) 2005-11-20
EA010787B1 (ru) 2008-10-30
CO5580793A2 (es) 2005-11-30
IL161894A (en) 2014-05-28

Similar Documents

Publication Publication Date Title
BR0214412A (pt) Solução para injeção de um antagonista de lhrh
ES2561108T3 (es) Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo
WO2007073486A3 (en) Methods and compositions for delivering active agents with enhanced pharmacological properties
MX2009000507A (es) Espuma farmaceutica de acidos grasos.
TW200628157A (en) Storage stable perfusion solution for dihydropteridinones
BRPI0606393A2 (pt) prevenção de doenças trombóticas com compostos ativos de vitamina d ou similares do mesmo
BRPI0514474A (pt) multiparticulados
BRPI0014869B8 (pt) prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
CO4890859A1 (es) Granulado para la preparacion de composiciones de rapida desintegracion y disolucion que contiene una elevada canti- dad de farmaco
AR060063A1 (es) Material cementicio, formulacion de material cementicio y articulo obtenido
NZ604417A (en) Liquid nasal spray containing low-dose naltrexone
PE20011223A1 (es) Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
MXPA03011480A (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral.
CA2412759A1 (en) Injectable solution of an lhrh antagonist
MXPA05005046A (es) Formulaciones parasiticidas topicas y metodos de tratamiento.
PE20011188A1 (es) El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoaria en mamiferos
RU2008146217A (ru) Фармацевтическая композиция, содержащая производное таксана, которая предназначена для приготовления инфузионного раствора, способ его приготовления и использование
CO5540279A2 (es) Formulacion liofilitada de 2-metil-tieno-benzodiazepina
PL1883392T3 (pl) Sposób wytwarzania izotonicznego wodnego roztworu iniekcyjnego ropiwakainy
PE20000018A1 (es) Composiciones farmaceuticas a base de dalfopristina y de quinupristina y su preparacion
PE20011320A1 (es) Suspension esteroidal estabilizada
EP1586581A3 (en) Non-Mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
WO2004075834A3 (en) Stabilized pharmaceutical compositions of safingol and methods of using the same
CN105579055A (zh) Lhrh类似物的水性缓释组合物

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: AETERNA ZENTARIS GMBH (DE)

Free format text: ALTERADO DE: ZENTARIS GMBH

B25A Requested transfer of rights approved

Owner name: ZENTARIS IVF GMBH (DE)

Free format text: TRANSFERIDO DE: AETERNA ZENTARIS GMBH

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/11/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 15/11/2022